Four-Month Tuberculosis Treatment Matches Six-Month Efficacy at IDWeek 2026
A new study reveals that a four-month TB treatment is as effective as the traditional six-month regimen without increasing recurrence rates.
Four-month TB treatment shows similar efficacy and safety to six-month therapy.
No recurrences of TB were noted within 12 months among evaluable patients.
The trial involved 270 low-risk adults with drug-susceptible pulmonary TB.
A recent study presented at IDWeek 2026 indicates that a four-month treatment regimen for tuberculosis (TB) can achieve results comparable to the conventional six-month therapy. This finding stems from the ESCAPE-TB2 randomized controlled trial, which focused on adults with low-risk, drug-susceptible pulmonary TB, suggesting a potential reduction in treatment duration without compromising patient safety or increasing the risk of disease recurrence.
The ESCAPE-TB2 trial, which spanned three years and included multiple centers, enrolled 270 participants diagnosed with low-risk pulmonary TB. The criteria for low-risk status included specific sputum smear results and limited lung involvement. Participants were randomly assigned to receive either a four-month treatment involving a combination of antibiotics or the standard six-month regimen, which consists of an initial two-month intensive phase followed by a continuation phase.
Preliminary results from the analysis of 167 randomized patients showed that adverse event rates were nearly identical between the two treatment groups, with 57.1% in the four-month group and 57.8% in the six-month group. Most adverse events were classified as mild, and treatment discontinuation due to side effects occurred in 18.5% of the shorter regimen group compared to 11.2% of the standard group, although this difference was not statistically significant.
Both treatment groups demonstrated high rates of sputum smear and culture conversion at various intervals throughout the study. Notably, no relapses or recurrences of TB were observed within a year following treatment, with a 100% disease-free survival rate among evaluable patients. These findings underscore the potential for a shorter treatment regimen to ease the burden on patients while maintaining effective outcomes.
Despite the promising results, researchers caution that these findings do not confirm noninferiority and may not be applicable to patients with more severe forms of TB. Further investigations are necessary to validate these results and assess the long-term implications of adopting a shorter treatment course in clinical practice.
